INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Beta Bionics, Inc. - BBNX

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Beta Bionics and its officers or directors, following a significant drop in the company's stock price after disappointing financial results [1][3]. Financial Performance - On January 8, 2026, Beta Bionics reported a preliminary financial result for Q4 2026, showing a 36% year-over-year increase in new patient starts, a decline from the previous quarter's 68% increase [3]. - Following the announcement, Beta Bionics' stock price fell by $11.85 per share, or 37.03%, closing at $20.15 per share on January 9, 2026 [3].